Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (481-490 of 692) with videos related to

Pageof 70
Sort By:
The Journal of Urology|January 12, 2022
Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor ApalutamideAlexander Pan, Rachel E Reingold, Jimmy L Zhao, et al.
EJNMMI Research|May 19, 2015
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumorsNeeta Pandit-Taskar, Joseph A O'Donoghue, Chaitanya R Divgi, et al.
Journal of Immunotherapy and Precision Oncology|December 25, 2023
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate CancerDaniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, et al.
Blood|February 3, 1998
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancerC I Rivas, J C Vera, F Delgado-López, et al.
European Urology Oncology|June 18, 2019
Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled TrialsSungmin Woo, Chong Hyun Suh, James A Eastham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomyZohar A Dotan, Fernando J Bianco, Farhang Rabbani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC countsD Lorente, D Olmos, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapyC N Sternberg, A Molina, S North, et al.
The Lancet. Oncology|October 13, 2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective studyRobert W Ross, Matthew D Galsky, Howard I Scher, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 10, 2010
Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAASAnn I Scher, Yuan Xu, Esther S C Korf, et al.
Pageof 70

Showing results (481-490 of 692) with videos related to

Sort By:
Pageof 70
The Journal of Urology|January 12, 2022
Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor ApalutamideAlexander Pan, Rachel E Reingold, Jimmy L Zhao, et al.
EJNMMI Research|May 19, 2015
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumorsNeeta Pandit-Taskar, Joseph A O'Donoghue, Chaitanya R Divgi, et al.
Journal of Immunotherapy and Precision Oncology|December 25, 2023
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate CancerDaniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, et al.
Blood|February 3, 1998
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancerC I Rivas, J C Vera, F Delgado-López, et al.
European Urology Oncology|June 18, 2019
Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled TrialsSungmin Woo, Chong Hyun Suh, James A Eastham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomyZohar A Dotan, Fernando J Bianco, Farhang Rabbani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC countsD Lorente, D Olmos, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapyC N Sternberg, A Molina, S North, et al.
The Lancet. Oncology|October 13, 2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective studyRobert W Ross, Matthew D Galsky, Howard I Scher, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 10, 2010
Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAASAnn I Scher, Yuan Xu, Esther S C Korf, et al.
Pageof 70